Progress in Brucella vaccine development

Abstract

Brucella spp. are zoonotic, facultative intracellular pathogens, which cause animal and human disease. Animal disease results in abortion of fetuses; in humans, it manifests flu-like symptoms with an undulant fever, with osteoarthritis as a common complication of infection. Antibiotic regimens for human brucellosis patients may last several months and are not always completely effective. While there are no vaccines for humans, several licensed live Brucella vaccines are available for use in livestock. The performance of these animal vaccines is dependent upon the host species, dose, and route of immunization. Newly engineered live vaccines, lacking well-defined virulence factors, retain low residual virulence, are highly protective, and may someday replace currently used animal vaccines. These also have possible human applications. Moreover, due to their enhanced safety and efficacy in animal models, subunit vaccines for brucellosis show great promise for their application in livestock and humans. This review summarizes the progress of brucellosis vaccine development and presents an overview of candidate vaccines.

Key words： Brucella; brucellosis; zoonosis; livestock vaccines

Acknowledgments

This work was supported by grants from National Institutes of Health Grant R21 AI-080960, 1R01 AI-093372, P20 RR020185, USDA-NIFA grant 2010-34397-21391, US Department of Agriculture Formula Funds, and Montana Agricultural Experiment Station.

References

1 Abu Shaqra Q M (2000). Epidemiological aspects of brucellosis in Jordan. Eur J Epidemiol, 16(6): 581-584

PMID

2 Adone R, Ciuchini F, Marianelli C, Tarantino M, Pistoia C, Marcon G, Petrucci P, Francia M, Riccardi G, Pasquali P (2005). Protective properties of rifampin-resistant rough mutants of Brucella melitensis. Infect Immun, 73(7): 4198-4204

PMID

3 Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godefroid J, Walravens K, Letesson J J (2001). Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect Immun, 69(8): 4816-4822

PMID

4 Alcantara R B, Read R D, Valderas M W, Brown T D, Roop R M 2nd (2004). Intact purine biosynthesis pathways are required for wild-type virulence of Brucella abortus 2308 in the BALB/c mouse model. Infect Immun, 72(8): 4911-4917

PMID

5 Almirón M, Martínez M, Sanjuan N, Ugalde R A (2001). Ferrochelatase is present in Brucella abortus and is critical for its intracellular survival and virulence. Infect Immun, 69(10): 6225-6230

PMID

6 Alton G G (1966). Duration of the immunity produced in goats by the Rev. 1 Brucella melitensis vaccine. J Comp Pathol, 76(3): 241-253

PMID

7 Alton G G (1968). Further studies on the duration of the immunity produced in goats by the Rev. 1 Brucella melitensis vaccine. J Comp Pathol, 78(2): 173-178

PMID

8 Arellano-Reynoso B, Lapaque N, Salcedo S, Briones G, Ciocchini A E, Ugalde R, Moreno E, Moriyón I, Gorvel J P (2005). Cyclic β-1,2-glucan is a Brucella virulence factor required for intracellular survival. Nat Immunol, 6(6): 618-625

PMID

9 Arenas-Gamboa A M, Ficht T A, Davis D S, Elzer P H, Kahl-McDonagh M, Wong-Gonzalez A, Rice-Ficht A C (2009a). Oral vaccination with microencapsuled strain 19 vaccine confers enhanced protection against Brucella abortus strain 2308 challenge in red deer (Cervus elaphus elaphus). J Wildl Dis, 45(4): 1021-1029

PMID

10 Arenas-Gamboa A M, Ficht T A, Davis D S, Elzer P H, Wong-Gonzalez A, Rice-Ficht A C (2009b). Enhanced immune response of red deer (Cervus elaphus) to live rb51 vaccine strain using composite microspheres. J Wildl Dis, 45(1): 165-173

PMID

11 Arenas-Gamboa A M, Ficht T A, Kahl-McDonagh M M, Gomez G, Rice-Ficht A C (2009c). The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infect Immun, 77(2): 877-884

PMID

12 Arenas-Gamboa A M, Ficht T A, Kahl-McDonagh M M, Rice-Ficht A C (2008). Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge. Infect Immun, 76(6): 2448-2455

PMID

13 Arenas-Gamboa A M, Rice-Ficht A C, Kahl-McDonagh M M, Ficht T A (2011). Protective efficacy and safety of Brucella melitensis 16MΔmucR against intraperitoneal and aerosol challenge in BALB/c mice. Infect Immun, 79(9): 3653-3658

PMID

14 Ascón M A, Ochoa-Repáraz J, Walters N, Pascual D W (2005). Partially assembled K99 fimbriae are required for protection. Infect Immun, 73(11): 7274-7280

PMID

15 Ashford D A, di Pietra J, Lingappa J, Woods C, Noll H, Neville B, Weyant R, Bragg S L, Spiegel R A, Tappero J, Perkins B A (2004). Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51. Vaccine, 22(25-26): 3435-3439

PMID

16 Atluri V L, Xavier M N, de Jong M F, den Hartigh A B, Tsolis R E (2011). Interactions of the human pathogenic Brucella species with their hosts. Annu Rev Microbiol, 65(1): 523-541

PMID

17 Audic S, Lescot M, Claverie J M, Scholz H C (2009). Brucella microti: the genome sequence of an emerging pathogen. BMC Genomics, 10(1): 352

PMID

18 Bäckhed F, Normark S, Schweda E K, Oscarson S, Richter-Dahlfors A (2003). Structural requirements for TLR4-mediated LPS signalling: a biological role for LPS modifications. Microbes Infect, 5(12): 1057-1063

PMID

19 Baldi, P.C., Wallach, J.C., Ferrero, M.C., Delpino, M.V., and Fossati, C.A. (2008). Occupational infection due to Brucella abortus S19 among workers involved in vaccine production in Argentina. CMI, 14: 805-807

20 Baloglu S, Boyle S M, Vemulapalli R, Sriranganathan N, Schurig G G, Toth T E (2005). Immune responses of mice to vaccinia virus recombinants expressing either Listeria monocytogenes partial listeriolysin or Brucella abortus ribosomal L7/L12 protein. Vet Microbiol, 109(1-2): 11-17

PMID

21 Banai M (2002). Control of small ruminant brucellosis by use of Brucella melitensis Rev.1 vaccine: laboratory aspects and field observations. Vet Microbiol, 90(1-4): 497-519

PMID

22 Bandara A B, Poff-Reichow S A, Nikolich M, Hoover D L, Sriranganathan N, Schurig G G, Dobrean V, Boyle S M (2009). Simultaneous expression of homologous and heterologous antigens in rough, attenuated Brucella melitensis. Microbes Infect, 11(3): 424-428

PMID

23 Barquero-Calvo E, Chaves-Olarte E, Weiss D S, Guzmán-Verri C, Chacón-Díaz C, Rucavado A, Moriyón I, Moreno E (2007). Brucella abortus uses a stealthy strategy to avoid activation of the innate immune system during the onset of infection. PLoS ONE, 2(7): e631

PMID

24 Barrio M B, Grilló M J, Muñoz P M, Jacques I, González D, de Miguel M J, Marín C M, Barberán M, Letesson J J, Gorvel J P, Moriyón I, Blasco J M, Zygmunt M S (2009). Rough mutants defective in core and O-polysaccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against Brucella melitensis infection of sheep. Vaccine, 27(11): 1741-1749

PMID

25 Barrionuevo P, Delpino M V, Velásquez L N, García Samartino C, Coria L M, Ibañez A E, Rodríguez M E, Cassataro J, Giambartolomei G H (2011). Brucella abortus inhibits IFN-γ-induced FcγRI expression and FcγRI-restricted phagocytosis via toll-like receptor 2 on human monocytes/macrophages. Microbes Infect, 13(3): 239-250

PMID

26 Beckett F W, MacDiarmid S C (1985). The effect of reduced-dose Brucella abortus strain 19 vaccination in accredited dairy herds. Br Vet J, 141(5): 507-514

PMID

27 Bercovich Z (2000). The use of skin delayed-type hypersensitivity as an adjunct test to diagnose brucellosis in cattle: a review. Vet Q, 22(3): 123-130

PMID

28 Bhattacharjee A K, Izadjoo M J, Zollinger W D, Nikolich M P, Hoover D L (2006). Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine. Infect Immun, 74(10): 5820-5825

PMID

29 Blasco J M, Díaz R (1993). Brucella melitensis Rev-1 vaccine as a cause of human brucellosis. Lancet, 342(8874): 805

PMID

30 Blasco J M, Marín C, Jiménez de Bagüés M P, Barberán M (1993). Efficacy of Brucella suis strain 2 vaccine against Brucella ovis in rams. Vaccine, 11(13): 1291-1294

PMID

31 Borts I H, McNUTT S H, Jordan C F (1946). Brucella melitensis isolated from swine tissues in Iowa. J Am Med Assoc, 130(14): 966-966

PMID

32 Boschiroli M L, Cravero S L, Arese A I, Campos E, Rossetti O L (1997). Protection against infection in mice vaccinated with a Brucella abortus mutant. Infect Immun, 65(2): 798-800

PMID

33 Bosseray N (1991). Brucella melitensis Rev. 1 living attenuated vaccine: stability of markers, residual virulence and immunogenicity in mice. Biologicals, 19(4): 355-363

PMID

34 Bosseray N, Plommet M (1990). Brucella suis S2, brucella melitensis Rev. 1 and Brucella abortus S19 living vaccines: residual virulence and immunity induced against three Brucella species challenge strains in mice. Vaccine, 8(5): 462-468

PMID

35 Briones G, Iñón de Iannino N, Roset M, Vigliocco A, Paulo P S, Ugalde R A (2001). Brucella abortus cyclic beta-1,2-glucan mutants have reduced virulence in mice and are defective in intracellular replication in HeLa cells. Infect Immun, 69(7): 4528-4535

PMID

36 Burkhardt S, Jiménez de Bagüés M P, Liautard J P, Köhler S (2005). Analysis of the behavior of eryC mutants of Brucella suis attenuated in macrophages. Infect Immun, 73(10): 6782-6790

PMID

37 Buyukcangaz E, Sen A (2007). The first isolation of Brucella melitensis from bovine aborted fetus in Turkey. J Biol Environ Sci, 1: 139-142

38 Cabrera A, Sáez D, Céspedes S, Andrews E, Oñate A (2009). Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice. Immunobiology, 214(6): 467-474

PMID

39 Caporale V, Bonfini B, Di Giannatale E, Di Provvido A, Forcella S, Giovannini A, Tittarelli M, Scacchia M (2010). Efficacy of Brucella abortus vaccine strain RB51 compared to the reference vaccine Brucella abortus strain 19 in water buffalo. Vet Ital, 46(1): 13-19, 5-11

PMID

40 Cardena A P, Herrera D M, Zamora J L F, Pina F B, Sanchez B M, Ruiz E J G, Williams J J, Alvarez F M, Castro R F (2009). Evaluation of vaccination with Brucella abortus S19 vaccine in cattle naturally infected with brucellosis in productive systems found in the Mexican Tropic. Int J Dairy Sci, 4(4): 142-151

41 Cassataro J, Estein S M, Pasquevich K A, Velikovsky C A, de la Barrera S, Bowden R, Fossati C A, Giambartolomei G H (2005). Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Infect Immun, 73(12): 8079-8088

PMID

42 Castaño M J, Solera J (2009). Chronic brucellosis and persistence of Brucella melitensis DNA. J Clin Microbiol, 47(7): 2084-2089

PMID

43 Centers for Disease Control and Prevention (CDC) (1998). Human exposure to Brucella abortus strain RB51—Kansas, 1997. MMWR Morb Mortal Wkly Rep, 47(9): 172-175

PMID

44 Cespedes S, Andrews E, Folch H, Oñate A (2000). Identification and partial characterisation of a new protective antigen of Brucella abortus. J Med Microbiol, 49(2): 165-170

PMID

45 Chacón-Díaz C, Muñoz-Rodríguez M, Barquero-Calvo E, Guzmán-Verri C, Chaves-Olarte E, Grilló M J, Moreno E (2011). The use of green fluorescent protein as a marker for Brucella vaccines. Vaccine, 29(3): 577-582

PMID

46 Chain P S, Comerci D J, Tolmasky M E, Larimer F W, Malfatti S A, Vergez L M, Aguero F, Land M L, Ugalde R A, Garcia E (2005). Whole-genome analyses of speciation events in pathogenic Brucellae. Infect Immun, 73(12): 8353-8361

PMID

47 Cheville N F, McCullough D R, Paulson L R (1998). Brucellosis in the greater Yellowstone area, Vol National Research Council (U.S.). Board on Agriculture. National Research Council (U.S.). Board on Environmental Studies and Toxicology, Washington, D.C., National Academy Press

48 Cheville N F, Olsen S C, Jensen A E, Stevens M G, Florance A M, Houng H S, Drazek E S, Warren R L, Hadfield T L, Hoover D L (1996a). Bacterial persistence and immunity in goats vaccinated with a purE deletion mutant or the parental 16M strain of Brucella melitensis. Infect Immun, 64(7): 2431-2439

PMID

49 Cheville N F, Olsen S C, Jensen A E, Stevens M G, Palmer M V, Florance A M (1996b). Effects of age at vaccination on efficacy of Brucella abortus strain RB51 to protect cattle against brucellosis. Am J Vet Res, 57(8): 1153-1156

PMID

50 Cheville N F, Stevens M G, Jensen A E, Tatum F M, Halling S M (1993). Immune responses and protection against infection and abortion in cattle experimentally vaccinated with mutant strains of Brucella abortus. Am J Vet Res, 54(10): 1591-1597

PMID

51 Clapp B, Skyberg J A, Yang X, Thornburg T, Walters N, Pascual D W (2011a). Protective live oral brucellosis vaccines stimulate Th1 and th17 cell responses. Infect Immun, 79(10): 4165-4174

PMID

52 Clapp B, Walters N, Thornburg T, Hoyt T, Yang X, Pascual D W (2011b). DNA vaccination of bison to brucellar antigens elicits elevated antibody and IFN-γ responses. J Wildl Dis, 47(3): 501-510

PMID

53 Cloeckaert A, Debbarh H S, Vizcaíno N, Saman E, Dubray G, Zygmunt M S (1996). Cloning, nucleotide sequence, and expression of the Brucella melitensis bp26 gene coding for a protein immunogenic in infected sheep. FEMS Microbiol Lett, 140(2-3): 139-144

PMID

54 Commander N J, Spencer S A, Wren B W, MacMillan A P (2007). The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Vaccine, 25(1): 43-54

PMID

55 Conde-Alvarez R, Grilló M J, Salcedo S P, de Miguel M J, Fugier E, Gorvel J P, Moriyón I, Iriarte M (2006). Synthesis of phosphatidylcholine, a typical eukaryotic phospholipid, is necessary for full virulence of the intracellular bacterial parasite Brucella abortus. Cell Microbiol, 8(8): 1322-1335

PMID

56 Confer A W, Hall S M, Faulkner C B, Espe B H, Deyoe B L, Morton R J, Smith R A (1985). Effects of challenge dose on the clinical and immune responses of cattle vaccinated with reduced doses of Brucella abortus strain 19. Vet Microbiol, 10(6): 561-575

PMID

57 Contreras-Rodriguez A, Ramirez-Zavala B, Contreras A, Schurig G G, Sriranganathan N, Lopez-Merino A (2003). Purification and characterization of an immunogenic aminopeptidase of Brucella melitensis. Infect Immun, 71(9): 5238-5244

PMID

58 Cook, W.E., Williams, E.S., Thorne, E.T., Kreeger, T.J., Stout, G., Bardsley, K., Edwards, H., Schurig, G., Colby, L.A., Enright, F., et al. (2002). Brucella abortus strain RB51 vaccination in elk. I. Efficacy of reduced dosage. J Wildl Dis, 38: 18-26

59 Corbel M J (1997). Brucellosis: an overview. Emerg Infect Dis, 3(2): 213-221

PMID

60 Crasta O R, Folkerts O, Fei Z, Mane S P, Evans C, Martino-Catt S, Bricker B, Yu G, Du L, Sobral B W (2008). Genome sequence of Brucella abortus vaccine strain S19 compared to virulent strains yields candidate virulence genes. PLoS ONE, 3(5): e2193

PMID

61 Da Costa Martins R, Irache J M, Blasco J M, Muñoz M P, Marín C M, Jesús Grilló M, Jesús De Miguel M, Barberán M, Gamazo C (2010). Evaluation of particulate acellular vaccines against Brucella ovis infection in rams. Vaccine, 28(17): 3038-3046

PMID

62 Davis D S, Elzer P H (2002). Brucella vaccines in wildlife. Vet Microbiol, 90(1-4): 533-544

PMID

63 Davis D S, Templeton J W, Ficht T A, Huber J D, Angus R D, Adams L G (1991). Brucella abortus in Bison. II. Evaluation of strain 19 vaccination of pregnant cows. J Wildl Dis, 27(2): 258-264

PMID

64 Delpino M V, Estein S M, Fossati C A, Baldi P C, Cassataro J (2007). Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine, 25(37-38): 6721-6729

PMID

65 den Hartigh A B, Sun Y H, Sondervan D, Heuvelmans N, Reinders M O, Ficht T A, Tsolis R M (2004). Differential requirements for VirB1 and VirB2 during Brucella abortus infection. Infect Immun, 72(9): 5143-5149

PMID

66 Diju I U (2009). Brucellosis—an under-estimated cause of arthralgia & muscular pains in general population. J Ayub Med Coll Abbottabad, 21(2): 128-131

PMID

67 Diptee M D, Adesiyun A A, Asgarali Z, Campbell M, Adone R (2006). Serologic responses, biosafety and clearance of four dosages of Brucella abortus strain RB51 in 6-10 months old water buffalo (Bubalus bubalis). Vet Immunol Immunopathol, 109(1-2): 43-55

PMID

68 Dornand J, Lafont V, Oliaro J, Terraza A, Castaneda-Roldan E, Liautard J P (2004). Impairment of intramacrophagic Brucella suis multiplication by human natural killer cells through a contact-dependent mechanism. Infect Immun, 72(4): 2303-2311

PMID

69 Dueñas A I, Orduña A, Crespo M S, García-Rodríguez C (2004). Interaction of endotoxins with Toll-like receptor 4 correlates with their endotoxic potential and may explain the proinflammatory effect of Brucella spp. LPS. Int Immunol, 16(10): 1467-1475

PMID

70 Dzata G K, Confer A W, Wyckoff J H 3rd (1991). The effects of adjuvants on immune responses in cattle injected with a Brucella abortus soluble antigen. Vet Microbiol, 29(1): 27-48

PMID

71 Ebel E D, Williams M S, Tomlinson S M (2008). Estimating herd prevalence of bovine brucellosis in 46 USA states using slaughter surveillance. Prev Vet Med, 85(3-4): 295-316

PMID

72 Edmonds M D, Cloeckaert A, Elzer P H (2002a). Brucella species lacking the major outer membrane protein Omp25 are attenuated in mice and protect against Brucella melitensis and Brucella ovis. Vet Microbiol, 88(3): 205-221

PMID

73 Edmonds M D, Cloeckaert A, Hagius S D, Samartino L E, Fulton W T, Walker J V, Enright F M, Booth N J, Elzer P H (2002b). Pathogenicity and protective activity in pregnant goats of a Brucella melitensis Deltaomp25 deletion mutant. Res Vet Sci, 72(3): 235-239

PMID

74 Eker A, Uzunca I, Tansel O, Birtane M (2011). A patient with brucellar cervical spondylodiscitis complicated by epidural abscess. J Clin Neurosci, 18(3): 428-430

PMID

75 el Idrissi A H, Benkirane A, el Maadoudi M, Bouslikhane M, Berrada J, Zerouali A (2001). Comparison of the efficacy of Brucella abortus strain RB51 and Brucella melitensis Rev. 1 live vaccines against experimental infection with Brucella melitensis in pregnant ewes. Rev Sci Tech, 20(3): 741-747

PMID

76 Elberg S S, Faunce K J Jr (1957). Immunization against Brucella infection. VI. Immunity conferred on goats by a nondependent mutant from a streptomycin-dependent mutant strain of Brucella melitensis. J Bacteriol, 73(2): 211-217

PMID

77 Elzer P H, Edmonds M D, Hagius S D, Walker J V, Gilsdorf M J, Davis D S (1998). Safety of Brucella abortus strain RB51 in Bison. J Wildl Dis, 34(4): 825-829

PMID

78 Entessar F, Ardalan A, Ebadi A, Jones L M (1967). Effect of living Rev. 1 vaccine in producing long-term immunity against Brucella melitensis infection in sheep in Iran. J Comp Pathol, 77(4): 367-376

PMID

79 Eschenbrenner M, Horn T A, Wagner M A, Mujer C V, Miller-Scandle T L, DelVecchio V G (2006). Comparative proteome analysis of laboratory grown Brucella abortus 2308 and Brucella melitensis 16M. J Proteome Res, 5(7): 1731-1740

PMID

80 Fensterbank R, Pardon P, Marly J (1982). Efficacy of Brucella melitensis Rev. 1 vaccine against Brucella ovis infection in rams. Ann Rech Vet, 13(2): 185-190

PMID

81 Ferguson G P, Datta A, Baumgartner J, Roop R M 2nd, Carlson R W, Walker G C (2004). Similarity to peroxisomal-membrane protein family reveals that Sinorhizobium and Brucella BacA affect lipid-A fatty acids. Proc Natl Acad Sci USA, 101(14): 5012-5017

PMID

82 Ferrero M C, Fossati C A, Baldi P C (2009). Smooth Brucella strains invade and replicate in human lung epithelial cells without inducing cell death. Microbes Infect, 11(4): 476-483

PMID

83 Fiorentino M A, Campos E, Cravero S, Arese A, Paolicchi F, Campero C, Rossetti O (2008). Protection levels in vaccinated heifers with experimental vaccines Brucella abortus M1-luc and INTA 2. Vet Microbiol, 132(3-4): 302-311

PMID

84 Fosgate G T, Adesiyun A A, Hird D W, Johnson W O, Hietala S K, Schurig G G, Ryan J, Diptee M D (2003). Evaluation of brucellosis RB51 vaccine for domestic water buffalo (Bubalus bubalis) in Trinidad. Prev Vet Med, 58(3-4): 211-225

PMID

85 Foulongne V, Walravens K, Bourg G, Boschiroli M L, Godfroid J, Ramuz M, O’Callaghan D (2001). Aromatic compound-dependent Brucella suis is attenuated in both cultured cells and mouse models. Infect Immun, 69(1): 547-550

PMID

86 Franco M P, Mulder M, Gilman R H, Smits H L (2007). Human brucellosis. Lancet Infect Dis, 7(12): 775-786

PMID

87 Galindo R C, Muñoz P M, de Miguel M J, Marin C M, Labairu J, Revilla M, Blasco J M, Gortazar C, de la Fuente J (2010). Gene expression changes in spleens of the wildlife reservoir species, Eurasian wild boar (Sus scrofa), naturally infected with Brucella suis biovar 2. J Genet Genomics, 37(11): 725-736

PMID

88 García-Carrillo C (1980). Comparison of B. melitensis Rev. 1 and B. abortus strain 19 as a vaccine against brucellosis in cattle. Zentralbl Veterinarmed B, 27(2): 131-138

PMID

89 González D, Grilló M J, De Miguel M J, Ali T, Arce-Gorvel V, Delrue R M, Conde-Alvarez R, Muñoz P, López-Goñi I, Iriarte M, Marín C M, Weintraub A, Widmalm G, Zygmunt M, Letesson J J, Gorvel J P, Blasco J M, Moriyón I (2008). Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export. PLoS ONE, 3(7): e2760

PMID

90 Graves R R (1943). The story of John M. Buck's and Matilda's contribution to the cattle industry. J Am Vet Med Assoc, 102: 193-195

91 Gulsun S, Aslan S, Satici O, Gul T (2011). Brucellosis in pregnancy. Trop Doct, 41(2): 82-84

PMID

92 Haag A F, Myka K K, Arnold M F, Caro-Hernández P, Ferguson G P (2010). Importance of lipopolysaccharide and cyclic β-1,2-glucans in Brucella-mammalian infections. Int J Microbiol, 2010: 1-12

PMID

93 Hall W H (1990). Modern chemotherapy for brucellosis in humans. Rev Infect Dis, 12(6): 1060-1099

PMID

94 Halling S M, Peterson-Burch B D, Bricker B J, Zuerner R L, Qing Z, Li L L, Kapur V, Alt D P, Olsen S C (2005). Completion of the genome sequence of Brucella abortus and comparison to the highly similar genomes of Brucella melitensis and Brucella suis. J Bacteriol, 187(8): 2715-2726

PMID

95 Herrera E, Rivera A, Palomares E G, Hernández-Castro R, Díaz-Aparicio E (2011). Isolation of Brucella melitensis from a RB51-vaccinated seronegative goat. Trop Anim Health Prod, 43(6): 1069-1070

PMID

96 Hofer E, Revilla-Fernández S, Al Dahouk S, Riehm J M, Nöckler K, Zygmunt M S, Cloeckaert A, Tomaso H, Scholz H C (2011). A potential novel Brucella species isolated from mandibular lymph nodes of red foxes in Austria. Vet Microbiol, (In press)

PMID

97 Jelastopulu E, Bikas C, Petropoulos C, Leotsinidis M (2008). Incidence of human brucellosis in a rural area in Western Greece after the implementation of a vaccination programme against animal brucellosis. BMC Public Health, 8(1): 241-245

PMID

98 Jiménez de Bagüés M P, Barberán M, Marín C M, Blasco J M (1995). The Brucella abortus RB51 vaccine does not confer protection against Brucella ovis in rams. Vaccine, 13(3): 301-304

PMID

99 Jiménez de Bagués M P, Marín C M, Barberán M, Blasco J M (1989). Responses of ewes to B. melitensis Rev1 vaccine administered by subcutaneous or conjunctival routes at different stages of pregnancy. Ann Rech Vet, 20(2): 205-213

PMID

100 Kaushik P, Singh D K, Kumar S V, Tiwari A K, Shukla G, Dayal S, Chaudhuri P (2010). Protection of mice against Brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides. Vet Res Commun, 34(2): 119-132

PMID

101 Keller R, Hilton T D, Rios H, Boedeker E C, Kaper J B (2010). Development of a live oral attaching and effacing Escherichia coli vaccine candidate using Vibrio cholerae CVD 103-HgR as antigen vector. Microb Pathog, 48(1): 1-8

PMID

102 Kim S, Lee D S, Watanabe K, Furuoka H, Suzuki H, Watarai M (2005). Interferon-γ promotes abortion due to Brucella infection in pregnant mice. BMC Microbiol, 5(1): 1-11

PMID

103 Kojouri G A, Gholami M (2009). Post vaccination follow-up of Brucella melitensis in blood stream of sheep by PCR assay. Comp Clin Pathol, 18(4): 439-442

104 Kolar J (1977). Brucella vaccines production in Mongolia. World Health Organization, Assignment Report on WHO Project MOG BLG 001, SEA/Vaccine/89, 40

105 Kreeger T J, Cook W E, Edwards W H, Elzer P H, Olsen S C (2002). Brucella abortus strain RB51 vaccination in elk. II. Failure of high dosage to prevent abortion. J Wildl Dis, 38(1): 27-31

PMID

106 Kreeger T J, Miller M W, Wild M A, Elzer P H, Olsen S C (2000). Safety and efficacy of Brucella abortus strain RB51 vaccine in captive pregnant elk. J Wildl Dis, 36(3): 477-483

PMID

107 Kurar E, Splitter G A (1997). Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response. Vaccine, 15(17-18): 1851-1857

PMID

108 Lavigne J P, Patey G, Sangari F J, Bourg G, Ramuz M, O’Callaghan D, Michaux-Charachon S (2005). Identification of a new virulence factor, BvfA, in Brucella suis. Infect Immun, 73(9): 5524-5529

PMID

109 Levine M M, Ferreccio C, Abrego P, Martin O S, Ortiz E, Cryz S (1999). Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine, 17(Suppl 2): S22-S27

PMID

110 Li Y K (1988). [A study on one strain of Brucella canis isolated from a cow at the first time]. Zhonghua Liu Xing Bing Xue Za Zhi, 9(6): 342-344

PMID

111 Loisel-Meyer S, Jiménez de Bagüés M P, Bassères E, Dornand J, Köhler S, Liautard J P, Jubier-Maurin V (2006). Requirement of norD for Brucella suis virulence in a murine model of in vitro and in vivo infection. Infect Immun, 74(3): 1973-1976

PMID

112 Lord V R, Schurig G G, Cherwonogrodzky J W, Marcano M J, Melendez G E (1998). Field study of vaccination of cattle with Brucella abortus strains RB51 and 19 under high and low disease prevalence. Am J Vet Res, 59(8): 1016-1020

PMID

113 Manthei C A (1959). Summary of controlled research with strain 19. Proc Annu Meet US Livest Sanit Assoc, 63: 91-97

114 Marín C M, Moreno E, Moriyón I, Díaz R, Blasco J M (1999). Performance of competitive and indirect enzyme-linked immunosorbent assays, gel immunoprecipitation with native hapten polysaccharide, and standard serological tests in diagnosis of sheep brucellosis. Clin Diagn Lab Immunol, 6(2): 269-272

PMID

115 Martínez de Tejada G, Pizarro-Cerdá J, Moreno E, Moriyón I (1995). The outer membranes of Brucella spp. are resistant to bactericidal cationic peptides. Infect Immun, 63(8): 3054-3061

PMID

116 Memish Z, Mah M W, Al Mahmoud S, Al Shaalan M, Khan M Y (2000). Brucella bacteraemia: clinical and laboratory observations in 160 patients. J Infect, 40(1): 59-63

PMID

117 Minas A, Minas M, Stournara A, Tselepidis S (2004). The “effects” of Rev-1 vaccination of sheep and goats on human brucellosis in Greece. Prev Vet Med, 64(1): 41-47

PMID

118 Mingle C K, Manthei C A, Jasmin A M (1941). The stability of reduced virulence exhibited by Brucella abortus strain 19. J Am Vet Med Assoc, 99: 203-204

119 Moreno E, Moriyón I (2001). Genus Brucella. In Dworkin (ed.), The procaryotes: an evolving microbiological resource for the microbiological community. Springer, New York, NY

120 Moriyón I, Grilló M J, Monreal D, González D, Marín C, López-Goñi I, Mainar-Jaime R C, Moreno E, Blasco J M (2004). Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res, 35(1): 1-38

PMID

121 Mukherjee F, Jain J, Grilló M J, Blasco J M, Nair M (2005). Evaluation of Brucella abortus S19 vaccine strains by bacteriological tests, molecular analysis of ery loci and virulence in BALB/c mice. Biologicals, 33(3): 153-160

PMID

122 Muñoz P M, de Miguel M J, Grilló M J, Marín C M, Barberán M, Blasco J M (2008). Immunopathological responses and kinetics of Brucella melitensis Rev 1 infection after subcutaneous or conjunctival vaccination in rams. Vaccine, 26(21): 2562-2569

PMID

123 Muñoz-Montesino C, Andrews E, Rivers R, González-Smith A, Moraga-Cid G, Folch H, Céspedes S, Oñate A A (2004). Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells. Infect Immun, 72(4): 2081-2087

PMID

124 O’Callaghan D, Maskell D, Liew F Y, Easmon C S, Dougan G (1988). Characterization of aromatic- and purine-dependent Salmonella typhimurium: attention, persistence, and ability to induce protective immunity in BALB/c mice. Infect Immun, 56(2): 419-423

PMID

125 Olsen S C (2010). Brucellosis in the United States: role and significance of wildlife reservoirs. Vaccine, 28(Suppl 5): F73-F76

PMID

126 Olsen S C, Boyle S M, Schurig G G, Sriranganathan N N (2009). Immune responses and protection against experimental challenge after vaccination of bison with Brucella abortus strain RB51 or RB51 overexpressing superoxide dismutase and glycosyltransferase genes. Clin Vaccine Immunol, 16(4): 535-540

PMID

127 Olsen S C, Fach S J, Palmer M V, Sacco R E, Stoffregen W C, Waters W R (2006). Immune responses of elk to initial and booster vaccinations with Brucella abortus strain RB51 or 19. Clin Vaccine Immunol, 13(10): 1098-1103

PMID

128 Olsen S C, Hennager S G (2010). Immune responses and protection against experimental Brucella suis biovar 1 challenge in nonvaccinated or B. abortus strain RB51-vaccinated cattle. Clin Vaccine Immunol, 17(12): 1891-1895

PMID

129 Olsen S C, Holland S D (2003). Safety of revaccination of pregnant bison with Brucella abortus strain RB51. J Wildl Dis, 39(4): 824-829

PMID

130 Olsen S C, Jensen A E, Stoffregen W C, Palmer M V (2003). Efficacy of calfhood vaccination with Brucella abortus strain RB51 in protecting bison against brucellosis. Res Vet Sci, 74(1): 17-22

PMID

131 Oñate A A, Donoso G, Moraga-Cid G, Folch H, Céspedes S, Andrews E (2005). An RNA vaccine based on recombinant Semliki Forest virus particles expressing the Cu,Zn superoxide dismutase protein of Brucella abortus induces protective immunity in BALB/c mice. Infect Immun, 73(6): 3294-3300

PMID

132 Osorio M, Wu Y, Singh S, Merkel T J, Bhattacharyya S, Blake M S, Kopecko D J (2009). Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge. Infect Immun, 77(4): 1475-1482

PMID

133 Palmer M V, Cheville N F, Jensen A E (1996a). Experimental infection of pregnant cattle with the vaccine candidate Brucella abortus strain RB51: pathologic, bacteriologic, and serologic findings. Vet Pathol, 33(6): 682-691

PMID

134 Palmer M V, Olsen S C, Gilsdorf M J, Philo L M, Clarke P R, Cheville N F (1996b). Abortion and placentitis in pregnant bison (Bison bison) induced by the vaccine candidate, Brucella abortus strain RB51. Am J Vet Res, 57(11): 1604-1607

PMID

135 Pappas G, Akritidis N, Bosilkovski M, Tsianos E (2005). Brucellosis. N Engl J Med, 352(22): 2325-2336

PMID

136 Pappas G, Panagopoulou P, Christou L, Akritidis N (2006a). Brucella as a biological weapon. Cell Mol Life Sci, 63(19-20): 2229-2236

PMID

137 Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos E V (2006b). The new global map of human brucellosis. Lancet Infect Dis, 6(2): 91-99

PMID

138 Pasquevich K A, Estein S M, García Samartino C, Zwerdling A, Coria L M, Barrionuevo P, Fossati C A, Giambartolomei G H, Cassataro J (2009). Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Infect Immun, 77(1): 436-445

PMID

139 Petrovska L, Hewinson R G, Dougan G, Maskell D J, Woodward M J (1999). Brucella melitensis 16M: characterisation of the galE gene and mouse immunisation studies with a galE deficient mutant. Vet Microbiol, 65(1): 21-36

PMID

140 Phillips R W, Elzer P H, Robertson G T, Hagius S D, Walker J V, Fatemi M B, Enright F M, Roop R M 2nd (1997). A Brucella melitensis high-temperature-requirement A (htrA) deletion mutant is attenuated in goats and protects against abortion. Res Vet Sci, 63(2): 165-167

PMID

141 Pishva E, Salehi M (2008). First report of isolation of Brucella melitensis, vaccine strain Rev.1 as a source of cattle infection in Iran. J Sci Islam Repub Iran, 19: 19-23

142 Poester, F.P., Goncalves, V.S., Paixao, T.A., Santos, R.L., Olsen, S.C., Schurig, G.G., and Lage, A.P. (2006). Efficacy of strain RB51 vaccine in heifers against experimental brucellosis. Vaccine, 24: 5327-5334

143 Pontes D S, Dorella F A, Ribeiro L A, Miyoshi A, Le Loir Y, Gruss A, Oliveira S C, Langella P, Azevedo V (2003). Induction of partial protection in mice after oral administration of Lactococcus lactis producing Brucella abortus L7/L12 antigen. J Drug Target, 11(8-10): 489-493

PMID

144 Pourbagher M A, Pourbagher A, Savas L, Turunc T, Demiroglu Y Z, Erol I, Yalcintas D (2006). Clinical pattern and abdominal sonographic findings in 251 cases of brucellosis in southern Turkey. AJR Am J Roentgenol, 187(2): W191-4

PMID

145 Pugh G W J Jr, Tabatabai L B, Bricker B J, Mayfield J E, Phillips M, Zehr E S, Belzer C A (1990). Immunogenicity of Brucella-extracted and recombinant protein vaccines in CD-1 and BALB/c mice. Am J Vet Res, 51(9): 1413-1420

PMID

146 Radwan A I, Bekairi S I, Mukayel A A, al-Bokmy A M, Prasad P V, Azar F N, Coloyan E R (1995). Control of Brucella melitensis infection in a large camel herd in Saudi Arabia using antibiotherapy and vaccination with Rev. 1 vaccine. Rev Sci Tech, 14(3): 719-732

PMID

147 Rafiei A, Ardestani S K, Kariminia A, Keyhani A, Mohraz M, Amirkhani A (2006). Dominant Th1 cytokine production in early onset of human brucellosis followed by switching towards Th2 along prolongation of disease. J Infect, 53(5): 315-324

PMID

148 Rajasekaran P, Surendran N, Seleem M N, Sriranganathan N, Schurig G G, Boyle S M (2011). Over-expression of homologous antigens in a leucine auxotroph of Brucella abortus strain RB51 protects mice against a virulent B. suis challenge. Vaccine, 29(17): 3106-3110

PMID

149 Rajashekara G, Krepps M, Eskra L, Mathison A, Montgomery A, Ishii Y, Splitter G (2005). Unraveling Brucella genomics and pathogenesis in immunocompromised IRF-1^-/- mice. Am J Reprod Immunol, 54(6): 358-368

PMID

150 Robertson G T, Elzer P H, Roop R M 2nd (1996). In vitro and in vivo phenotypes resulting from deletion of the high temperature requirement A (htrA) gene from the bovine vaccine strain Brucella abortus S19. Vet Microbiol, 49(3-4): 197-207

PMID

151 Roop R M 2nd, Jeffers G, Bagchi T, Walker J, Enright F M, Schurig G G (1991). Experimental infection of goat fetuses in utero with a stable, rough mutant of Brucella abortus. Res Vet Sci, 51(2): 123-127

PMID

152 Roop R M 2nd, Phillips R W, Hagius S, Walker J V, Booth N J, Fulton W T, Edmonds M D, Elzer P H (2001). Re-examination of the role of the Brucella melitensis HtrA stress response protease in virulence in pregnant goats. Vet Microbiol, 82(1): 91-95

PMID

153 Roth F, Zinsstag J, Orkhon D, Chimed-Ochir G, Hutton G, Cosivi O, Carrin G, Otte J (2003). Human health benefits from livestock vaccination for brucellosis: case study. Bull World Health Organ, 81(12): 867-876

PMID

154 Sangari F J, Agüero J (1994). Identification of Brucella abortus B19 vaccine strain by the detection of DNA polymorphism at the ery locus. Vaccine, 12(5): 435-438

PMID

155 Sangari F J, García-Lobo J M, Agüero J (1994). The Brucella abortus vaccine strain B19 carries a deletion in the erythritol catabolic genes. FEMS Microbiol Lett, 121(3): 337-342

PMID

156 Schlabritz-Loutsevitch N E, Whatmore A M, Quance C R, Koylass M S, Cummins L B, Dick E J Jr, Snider C L, Cappelli D, Ebersole J L, Nathanielsz P W, Hubbard G B (2009). A novel Brucella isolate in association with two cases of stillbirth in non-human primates- first report. J Med Primatol, 38(1): 70-73

PMID

157 Schurig G G, Roop R M 2nd, Bagchi T, Boyle S, Buhrman D, Sriranganathan N (1991). Biological properties of RB51; a stable rough strain of Brucella abortus. Vet Microbiol, 28(2): 171-188

PMID

158 SCOFCAH (2011). Portugal: Results of the implementation of the sheep and goat brucellosis eradication programme 2010 Standing Committee on the Food Chain and Animal Health (SCOFCAH), Brusselshttp://ec.europa.eu/food/committees/regulatory/scfcah/animal_health/presentations/0708092011_brucellosis_portugal.pdf

159 Scurlock B M, Edwards W H (2010). Status of brucellosis in free-ranging elk and bison in Wyoming. J Wildl Dis, 46(2): 442-449

PMID

160 Shi D, Song Y, Li Y J (2006). [Progress on lactococcus lactis expressing heterologous antigens as live mucosal vaccines]. Wei Sheng Wu Xue Bao, 46(4): 680-683

PMID

161 Silva T M, Costa E A, Paixão T A, Tsolis R M, Santos R L (2011a). Laboratory animal models for brucellosis research. J Biomed Biotechnol, 2011: 518323

PMID

162 Silva T M, Paixão T A, Costa E A, Xavier M N, Sá J C, Moustacas V S, den Hartigh A B, Carvalho Neta A V, Oliveira S C, Tsolis R, Santos R L (2011b). Putative ATP-binding cassette transporter is essential for Brucella ovis pathogenesis in mice. Infect Immun, 79(4): 1706-1717

PMID

163 Smith L D, Ficht T A (1990). Pathogenesis of Brucella. Crit Rev Microbiol, 17(3): 209-230

PMID

164 Smither S J, Perkins S D, Davies C, Stagg A J, Nelson M, Atkins H S (2009). Development and characterization of mouse models of infection with aerosolized Brucella melitensis and Brucella suis. Clin Vaccine Immunol, 16(5): 779-783

PMID

165 Spink W W, Hall J W 3rd, Finstad J, Mallet E (1962). Immunization with viable Brucella organisms. Results of a safety test in humans. Bull World Health Organ, 26: 409-419

PMID

166 Stabel T J, Mayfield J E, Morfitt D C, Wannemuehler M J (1993). Oral immunization of mice and swine with an attenuated Salmonella choleraesuis [delta cya-12 delta(crp-cdt)19] mutant containing a recombinant plasmid. Infect Immun, 61(2): 610-618

PMID

167 Stabel T J, Mayfield J E, Tabatabai L B, Wannemuehler M J (1990). Oral immunization of mice with attenuated Salmonella typhimurium containing a recombinant plasmid which codes for production of a 31-kilodalton protein of Brucella abortus. Infect Immun, 58(7): 2048-2055

PMID

168 Stabel T J, Mayfield J E, Tabatabai L B, Wannemuehler M J (1991). Swine immunity to an attenuated Salmonella typhimurium mutant containing a recombinant plasmid which codes for production of a 31-kilodalton protein of Brucella abortus. Infect Immun, 59(9): 2941-2947

PMID

169 Stevens M G, Hennager S G, Olsen S C, Cheville N F (1994). Serologic responses in diagnostic tests for brucellosis in cattle vaccinated with Brucella abortus 19 or RB51. J Clin Microbiol, 32(4): 1065-1066

PMID

170 Stevens M G, Olsen S C (1996). Antibody responses to Brucella abortus 2308 in cattle vaccinated with B. abortus RB51. Infect Immun, 64(3): 1030-1034

PMID

171 Stevens M G, Olsen S C, Cheville N F (1995a). Comparative analysis of immune responses in cattle vaccinated with Brucella abortus strain 19 or strain RB51. Vet Immunol Immunopathol, 44(3-4): 223-235

PMID

172 Stevens M G, Olsen S C, Pugh G W Jr, Brees D (1995b). Comparison of immune responses and resistance to brucellosis in mice vaccinated with Brucella abortus 19 or RB51. Infect Immun, 63(1): 264-270

PMID

173 Taylor A W, McDiarmid A (1949). The stability of the avirulent characters of Brucella abortus, strain 19 and strain 45/20 in lactating and pregnant cows. Vet Rec, 61: 317-318

174 Teske S S, Huang Y, Tamrakar S B, Bartrand T A, Weir M H, Haas C N (2011). Animal and human dose-response models for Brucella species. Risk Anal, 31(10): 1576-1596

PMID

175 Thorne E T (1997). Brucellosis, bison, elk, and cattle in the Greater Yellowstone area: defining the problem, exploring solutions. Cheyenne, Wyoming Game and Fish Dept. for Greater Yellowstone Interagency Brucellosis Committee

176 Tibor A, Jacques I, Guilloteau L, Verger J M, Grayon M, Wansard V, Letesson J J (1998). Effect of P39 gene deletion in live Brucella vaccine strains on residual virulence and protective activity in mice. Infect Immun, 66(11): 5561-5564

PMID

177 Trant C G, Lacerda T L, Carvalho N B, Azevedo V, Rosinha G M, Salcedo S P, Gorvel J P, Oliveira S C (2010). The Brucella abortus phosphoglycerate kinase mutant is highly attenuated and induces protection superior to that of vaccine strain 19 in immunocompromised and immunocompetent mice. Infect Immun, 78(5): 2283-2291

PMID

178 Treanor J J, Johnson J S, Wallen R L, Cilles S, Crowley P H, Cox J J, Maehr D S, White P J, Plumb G E (2010). Vaccination strategies for managing brucellosis in Yellowstone bison. Vaccine, 28(Suppl 5): F64-F72

PMID

179 Ugalde J E, Comerci D J, Leguizamón M S, Ugalde R A (2003). Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a new live rough-phenotype vaccine. Infect Immun, 71(11): 6264-6269

PMID

180 Valderas M W, Barrow W W (2008). Establishment of a method for evaluating intracellular antibiotic efficacy in Brucella abortus-infected Mono Mac 6 monocytes. J Antimicrob Chemother, 61(1): 128-134

PMID

181 Van Campen H, Rhyan J (2010). The role of wildlife in diseases of cattle. Vet Clin North Am Food Anim Pract, 26(1): 147-161

PMID

182 Velikovsky C A, Cassataro J, Giambartolomei G H, Goldbaum F A, Estein S, Bowden R A, Bruno L, Fossati C A, Spitz M (2002). A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infect Immun, 70(5): 2507-2511

PMID

183 Vemulapalli R, Contreras A, Sanakkayala N, Sriranganathan N, Boyle S M, Schurig G G (2004). Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice. Vet Microbiol, 102(3-4): 237-245

PMID

184 Verger J M, Grayon M, Zundel E, Lechopier P, Olivier-Bernardin V (1995). Comparison of the efficacy of Brucella suis strain 2 and Brucella melitensis Rev. 1 live vaccines against a Brucella melitensis experimental infection in pregnant ewes. Vaccine, 13(2): 191-196

PMID

185 Walker, G.C., LeVier, K., Phillips, R.W., Grippe, V.K., and Roop, R.M., 2nd. (2000). Similar requirements of a plant symbiont and a mammalian pathogen for prolonged intracellular survival. Science, 287: 2492-2493

186 Wang Y, Bai Y, Qu Q, Xu J, Chen Y, Zhong Z, Qiu Y, Wang T, Du X, Wang Z, Yu S, Fu S, Yuan J, Zhen Q, Yu Y, Chen Z, Huang L (2011). The 16MΔvjbR as an ideal live attenuated vaccine candidate for differentiation between Brucella vaccination and infection. Vet Microbiol, 151(3-4): 354-362

PMID

187 Ward D, Jackson, R., Karomatullo H, Khakimov T, Kurbonov K, Amirbekov M, Stack J, El-Idrissi A, Heuer C (2011). Brucellosis control in Tajikistan using Rev 1 vaccine: change in seroprevalence in small ruminants from 2004 to 2009. Vet Rec

188 Whatmore A M (2009). Current understanding of the genetic diversity of Brucella, an expanding genus of zoonotic pathogens. Infect Genet Evol, 9(6): 1168-1184

PMID

189 Winter A J, Rowe G E, Duncan J R, Eis M J, Widom J, Ganem B, Morein B (1988). Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice. Infect Immun, 56(11): 2808-2817

PMID

190 Wise R I (1980). Brucellosis in the United States. Past, present, and future. JAMA, 244(20): 2318-2322

PMID

191 Wyckoff J H 3rd, Howland J L, Scott C M, Smith R A, Confer A W (2005). Recombinant bovine interleukin 2 enhances immunity and protection induced by Brucella abortus vaccines in cattle. Vet Microbiol, 111(1-2): 77-87

PMID

192 Xavier M N, Paixão T A, Poester F P, Lage A P, Santos R L (2009). Pathological, immunohistochemical and bacteriological study of tissues and milk of cows and fetuses experimentally infected with Brucella abortus. J Comp Pathol, 140(2-3): 149-157

PMID

193 Xin X (1986). Orally administrable brucellosis vaccine: Brucella suis strain 2 vaccine. Vaccine, 4(4): 212-216

PMID

194 Yang X, Becker T, Walters N, Pascual D W (2006). Deletion of znuA virulence factor attenuates Brucella abortus and confers protection against wild-type challenge. Infect Immun, 74(7): 3874-3879

PMID

195 Yang X, Hinnebusch B J, Trunkle T, Bosio C M, Suo Z, Tighe M, Harmsen A, Becker T, Crist K, Walters N, Avci R, Pascual D W (2007). Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague. J Immunol, 178(2): 1059-1067

PMID

196 Yang X, Hudson M, Walters N, Bargatze R F, Pascual D W (2005). Selection of protective epitopes for Brucella melitensis by DNA vaccination. Infect Immun, 73(11): 7297-7303

PMID

197 Yang X, Thornburg T, Walters N, Pascual D W (2010). DeltaznuADeltapurE Brucella abortus 2308 mutant as a live vaccine candidate. Vaccine, 28(4): 1069-1074

PMID

198 Yang Y, Yin J, Guo D, Lang X, Wang X (2011). Immunization of mice with recombinant S-adenosyl-L-homocysteine hydrolase protein confers protection against Brucella melitensis infection. FEMS Immunol Med Microbiol, 61(2): 159-167

PMID

199 Young E J (1989). Clinical manifestations of human brucellosis, p. 97-126. In E. J. Young and M. J. Corbel (ed.), Brucellosis: clinical and laboratory aspects. CRC Press, Inc, Boca Raton, Fla

200 Yu D H, Hu X D, Cai H, Li M (2007). A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses. DNA Cell Biol, 26(6): 435-443

PMID

201 Zhan Y, Cheers C (1993). Endogenous gamma interferon mediates resistance to Brucella abortus infection. Infect Immun, 61(11): 4899-4901

PMID

202 Zhao Z, Li M, Luo D, Xing L, Wu S, Duan Y, Yang P, Wang X (2009). Protection of mice from Brucella infection by immunization with attenuated Salmonella enterica serovar typhimurium expressing A L7/L12 and BLS fusion antigen of Brucella. Vaccine, 27(38): 5214-5219

PMID

203 Zinsstag J, Roth F, Orkhon D, Chimed-Ochir G, Nansalmaa M, Kolar J, Vounatsou P (2005). A model of animal-human brucellosis transmission in Mongolia. Prev Vet Med, 69(1-2): 77-95

PMID

204 Zowghi E, Ebadi A (1985). Naturally occurring Brucella melitensis infection in cattle in Iran. Rev Sci Tech Off Int Epiz, 4: 811-814